The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and Safety of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: The ASSENT-3 Randomized Trial in Acute MI - ASSENT 3

Description:

The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 is a randomized trial that compared the efficacy and safety of tenecteplase plus enoxaparin or abciximab, with that of tenecteplase plus weight-adjusted unfractionated heparin (UFH) in patients with acute myocardial infarction (AMI).